Published in Cell Death Differ on April 01, 2004
Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86
Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell (2012) 1.79
The enigma of caspase-2: the laymen's view. Cell Death Differ (2008) 1.63
Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem (2009) 1.47
Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron (2010) 1.45
Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev (2009) 1.37
Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem (2009) 1.34
Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet (2010) 1.33
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol (2009) 1.30
Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res (2011) 1.17
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta (2011) 1.16
Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet (2012) 1.16
Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci (2010) 1.10
Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist (2011) 1.08
Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol (2010) 1.02
Mouse models of Huntington disease: variations on a theme. Dis Model Mech (2009) 1.02
Structural basis for executioner caspase recognition of P5 position in substrates. Apoptosis (2008) 0.99
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
Fibrils colocalize caspase-3 with procaspase-3 to foster maturation. J Biol Chem (2012) 0.97
Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation. EMBO J (2015) 0.95
Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell Mol Neurobiol (2007) 0.93
Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res (2009) 0.92
Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease. Neurol Res Int (2011) 0.92
Zinc-mediated allosteric inhibition of caspase-6. J Biol Chem (2012) 0.92
Allosteric peptides bind a caspase zymogen and mediate caspase tetramerization. Nat Chem Biol (2012) 0.91
The role of caspase-2 in stress-induced apoptosis. J Cell Mol Med (2010) 0.91
Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci (2012) 0.90
Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J Biol Chem (2011) 0.90
Caspases as therapeutic targets. J Cell Mol Med (2008) 0.89
Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol (2012) 0.86
Huntington's disease: the past, present, and future search for disease modifiers. Yale J Biol Med (2013) 0.85
Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Mol Neurodegener (2011) 0.83
A whole cell assay to measure caspase-6 activity by detecting cleavage of lamin A/C. PLoS One (2012) 0.83
Involvement of subtype 1 metabotropic glutamate receptors in apoptosis and caspase-7 over-expression in spinal cord of neuropathic rats. Pharmacol Res (2008) 0.83
Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats. PLoS One (2014) 0.82
Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy. Int J Biomed Sci (2011) 0.82
From pathways to targets: understanding the mechanisms behind polyglutamine disease. Biomed Res Int (2014) 0.81
Discovery of novel isoforms of huntingtin reveals a new hominid-specific exon. PLoS One (2015) 0.81
The Golgi complex in stress and death. Front Neurosci (2015) 0.80
Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo. J Biol Chem (2015) 0.79
Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression. PLoS One (2012) 0.79
Caspase-2 promotes cytoskeleton protein degradation during apoptotic cell death. Cell Death Dis (2013) 0.78
A knockout of the caspase 2 gene produces increased resistance of the nigrostriatal dopaminergic pathway to MPTP-induced toxicity. Exp Neurol (2011) 0.77
Molecular mapping of striatal subdivisions in juvenile Macaca Mulata. Exp Neurol (2006) 0.75
Proteolytic cleavage of ataxin-7 promotes SCA7 retinal degeneration and neurological dysfunction. Hum Mol Genet (2015) 0.75
Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP. J Neurosci (2016) 0.75
Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice. PLoS One (2013) 0.75
Caspase-6 Undergoes a Distinct Helix-Strand Interconversion upon Substrate Binding. J Biol Chem (2017) 0.75
Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. Front Mol Neurosci (2017) 0.75
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 7.24
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg (1985) 5.91
Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med (1967) 5.88
The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Induction of neurogenesis in the neocortex of adult mice. Nature (2000) 5.04
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell (1995) 4.53
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science (1993) 4.53
Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science (1999) 4.43
Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ (2004) 4.41
Immortalization of hypothalamic GnRH neurons by genetically targeted tumorigenesis. Neuron (1990) 4.15
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature (1988) 3.90
Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med (1999) 3.72
A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet (2001) 3.59
Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science (1996) 3.53
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest (1996) 3.42
A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med (2000) 3.24
An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A (2000) 3.13
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet (1996) 3.08
Induction of apoptosis by the low-affinity NGF receptor. Science (1993) 3.04
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem (1998) 2.93
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem (2001) 2.86
The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet (1997) 2.84
The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature (1998) 2.81
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 2.65
Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem (2000) 2.62
Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet (1992) 2.53
Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A (1996) 2.50
Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene (1994) 2.49
Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet (1998) 2.42
bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci U S A (1993) 2.39
Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J Neurosci (1998) 2.39
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development (1996) 2.35
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum (1966) 2.32
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood (1998) 2.31
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Oromandibular reconstruction with the radial-forearm osteocutaneous flap: experience with 60 consecutive cases. Plast Reconstr Surg (1999) 2.30
Sensory neuropathy with low-dose pyridoxine. Neurology (1985) 2.30
A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med (1974) 2.29
Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med (1986) 2.29
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem (1998) 2.23
Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG)n. Nucleic Acids Res (1990) 2.23
Ultra-low dose intravenous heparin in the prevention of postoperative deep-vein thrombosis. Lancet (1980) 2.20
The AKT kinase is activated in multiple myeloma tumor cells. Blood (2001) 2.20
Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature (1985) 2.19
Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res (1997) 2.16
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem (1996) 2.14
A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet (1999) 2.12
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol (1999) 2.10
HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet (1997) 2.09
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet (1999) 2.02
Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. J Neurosci (1997) 2.01
Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci (1998) 1.99
Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke (1994) 1.99
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest (2000) 1.98
BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol (2001) 1.97
Human Bcl-2 reverses survival defects in yeast lacking superoxide dismutase and delays death of wild-type yeast. J Cell Biol (1997) 1.97
Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res (1996) 1.97
A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet (1994) 1.97
Colchicine inhibition of casein-induced amyloidosis in mice. Isr J Med Sci (1974) 1.96
Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition. Proc Natl Acad Sci U S A (1996) 1.95